Rationale and design of a multicenter randomized clinical trial of extended release gabapentin in provoked vestibulodynia and biological correlates of response.

[1]  Rao P. Gullapalli,et al.  The role of circulating sex hormones in menstrual cycle–dependent modulation of pain-related brain activation , 2013, PAIN.

[2]  V. Biton,et al.  A gastroretentive gabapentin formulation for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double-blind, randomized, controlled clinical trial. , 2012, Diabetes research and clinical practice.

[3]  M. Rowbotham,et al.  Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations , 2012, PAIN.

[4]  R. LaMotte,et al.  Sensory responses to injection and punctate application of capsaicin and histamine to the skin , 2011, PAIN.

[5]  T. Morgan,et al.  Differences in Primary Compared With Secondary Vestibulodynia by Immunohistochemistry , 2011, Obstetrics and gynecology.

[6]  J. Andrews.  Vulvodynia Interventions—Systematic Review and Evidence Grading , 2011, Obstetrical & gynecological survey.

[7]  P. Wiffen,et al.  Gabapentin for chronic neuropathic pain and fibromyalgia in adults. , 2011, The Cochrane database of systematic reviews.

[8]  Cuiping Chen,et al.  Pharmacokinetics of Gabapentin in a Novel Gastric‐Retentive Extended‐Release Formulation: Comparison With an Immediate‐Release Formulation and Effect of Dose Escalation and Food , 2011, Journal of clinical pharmacology.

[9]  Ulf Leser,et al.  Species identification for gene name normalization , 2010, BMC Bioinformatics.

[10]  R. Dworkin,et al.  Oral Desipramine and Topical Lidocaine for Vulvodynia: A Randomized Controlled Trial , 2010, Obstetrics and gynecology.

[11]  Hong Li,et al.  Histologic and receptor analysis of primary and secondary vestibulodynia and controls: a prospective study. , 2010, American journal of obstetrics and gynecology.

[12]  Richard E. White,et al.  Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations , 2010, PAIN®.

[13]  S. Khalifé,et al.  Provoked vestibulodynia: psychological predictors of topical and cognitive-behavioral treatment outcome. , 2010, Behaviour research and therapy.

[14]  L. McLean,et al.  Pelvic floor muscle assessment outcomes in women with and without provoked vestibulodynia and the impact of a physical therapy program. , 2010, The journal of sexual medicine.

[15]  Ramin Homayouni,et al.  Slim-Prim: an integrated data system for clinical and translational research , 2009, BMC Bioinformatics.

[16]  Teeradache Viangteeravat,et al.  Biomedical Informatics Unit (BMIU): Slim‐Prim System Bridges the Gap Between Laboratory Discovery and Practice , 2009, Clinical and translational science.

[17]  R. Dworkin,et al.  The Tampon Test for Vulvodynia Treatment Outcomes Research: Reliability, Construct Validity, and Responsiveness , 2009, Obstetrics and gynecology.

[18]  Candace S. Brown,et al.  Self-management, amitriptyline, and amitripyline plus triamcinolone in the management of vulvodynia. , 2009, Journal of women's health.

[19]  C. Raker,et al.  Topical Gabapentin in the Treatment of Localized and Generalized Vulvodynia , 2008, Obstetrics and gynecology.

[20]  Ananda Sen,et al.  Vulvodynia Incidence and Remission Rates Among Adult Women: A 2-Year Follow-up Study , 2008, Obstetrics and gynecology.

[21]  T. Gordi,et al.  Pharmacokinetics of gabapentin after a single day and at steady state following the administration of gastric-retentive- extended-release and immediate-release tablets: a randomized, open-label, multiple-dose, three-way crossover, exploratory study in healthy subjects. , 2008, Clinical therapeutics.

[22]  B. Appelhans,et al.  Heart rate variability and pain: Associations of two interrelated homeostatic processes , 2008, Biological Psychology.

[23]  David Cella,et al.  Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. , 2008, The journal of pain : official journal of the American Pain Society.

[24]  R. Dworkin,et al.  Clinical trial outcome in neuropathic pain , 2008, Neurology.

[25]  T. Kuiken,et al.  Vaginal Pressure-Pain Thresholds: Initial Validation and Reliability Assessment in Healthy Women , 2008, The Clinical journal of pain.

[26]  J. Farrar,et al.  Pharmacologic management of neuropathic pain: Evidence-based recommendations , 2007, PAIN.

[27]  L. Sahlin,et al.  Steroid receptor expression in the vulvar vestibular mucosa--effects of oral contraceptives and menstrual cycle. , 2007, Contraception.

[28]  P. Keck,et al.  Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. , 2007, Arthritis and rheumatism.

[29]  A. Borgida,et al.  Evaluation of Gabapentin in the Treatment of Generalized Vulvodynia, Unprovoked , 2007, The Journal of reproductive medicine.

[30]  G. Bachmann,et al.  Assessment of vulvodynia symptoms in a sample of US women: a prevalence survey with a nested case control study. , 2007, American journal of obstetrics and gynecology.

[31]  T. Nurmikko,et al.  EFNS guidelines on pharmacological treatment of neuropathic pain , 2006, European journal of neurology.

[32]  C. Gardella.  Vulvar vestibulitis syndrome , 2006, Current infectious disease reports.

[33]  W. Maixner,et al.  A Conceptual Model for the Pathophysiology of Vulvar Vestibulitis Syndrome , 2006, Obstetrical & gynecological survey.

[34]  J. Mckenney,et al.  Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. , 2006, The American journal of cardiology.

[35]  G. Bachmann,et al.  Vulvodynia: Characteristics and Associations With Comorbidities and Quality of Life , 2006, Obstetrics and gynecology.

[36]  A. Mykletun,et al.  The hospital anxiety and depression rating scale: A cross-sectional study of psychometrics and case finding abilities in general practice , 2005, BMC psychiatry.

[37]  R. Dworkin,et al.  Effects of intradermal foot and forearm capsaicin injections in normal and vulvodynia-afflicted women , 2005, Pain.

[38]  M. Granot,et al.  Psychological Factors Associated with Perception of Experimental Pain in Vulvar Vestibulitis Syndrome , 2005, Journal of sex & marital therapy.

[39]  M. Bushnell,et al.  Neural correlates of painful genital touch in women with vulvar vestibulitis syndrome , 2005, Pain.

[40]  M. Moyal-Barracco,et al.  The Vulvodynia Guideline , 2005, Journal of lower genital tract disease.

[41]  P. Rothwell.  External validity of randomised controlled trials: “To whom do the results of this trial apply?” , 2005, The Lancet.

[42]  E. Torebjörk,et al.  Decreased mechanical pain threshold in the vestibular mucosa of women using oral contraceptives: a contributing factor in vulvar vestibulitis? , 2004, The Journal of reproductive medicine.

[43]  M. Moyal-Barracco,et al.  2003 ISSVD terminology and classification of vulvodynia: a historical perspective. , 2004, The Journal of reproductive medicine.

[44]  D. Yarnitsky,et al.  Primary and secondary vulvar vestibulitis syndrome: systemic pain perception and psychophysical characteristics. , 2004, American journal of obstetrics and gynecology.

[45]  D. Yarnitsky,et al.  Association between quantitative sensory testing, treatment choice, and subsequent pain reduction in vulvar vestibulitis syndrome. , 2004, The journal of pain : official journal of the American Pain Society.

[46]  J. Farrar,et al.  Core outcome measures for chronic pain clinical trials: IMMPACT recommendations , 2003, Pain.

[47]  J. Farrar,et al.  Core outcome domains for chronic pain clinical trials: IMMPACT recommendations , 2003, Pain.

[48]  T. Tomson,et al.  Serum Concentrations and Effects of Gabapentin and Vigabatrin: Observations from a Dose Titration Study , 2003, Therapeutic drug monitoring.

[49]  J. Ware,et al.  Interpreting incomplete data in studies of diet and weight loss. , 2003, The New England journal of medicine.

[50]  J. Brisson,et al.  Use of oral contraceptive pills and vulvar vestibulitis: a case-control study. , 2002, American journal of epidemiology.

[51]  D. Foster.  Vulvar Disease , 2002, Obstetrics and gynecology.

[52]  R. Amsel,et al.  Vestibular tactile and pain thresholds in women with vulvar vestibulitis syndrome , 2002, Pain.

[53]  M. Hilliges,et al.  The expression of cyclooxygenase 2 and inducible nitric oxide synthase indicates no active inflammation in vulvar vestibulitis , 2001, Acta obstetricia et gynecologica Scandinavica.

[54]  Y. Binik,et al.  Vulvar Vestibulitis Syndrome: Reliability of Diagnosis and Evaluation of Current Diagnostic Criteria , 2001, Obstetrics and gynecology.

[55]  P. Munday.  Response to treatment in dysaesthetic vulvodynia , 2001, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

[56]  M. Rowbotham,et al.  Capsaicin evoked pain and allodynia in post-herpetic neuralgia , 2000, Pain.

[57]  L. Sadownik.  Clinical profile of vulvodynia patients. A prospective study of 300 patients. , 2000, The Journal of reproductive medicine.

[58]  Candace S. Brown,et al.  The Female Sexual Function Index (FSFI): A Multidimensional Self-Report Instrument for the Assessment of Female Sexual Function , 2000, Journal of sex & marital therapy.

[59]  B. Ben-david,et al.  Gabapentin therapy for vulvodynia. , 1999, Anesthesia and analgesia.

[60]  A. Beydoun,et al.  Gabapentin for the Symptomatic Treatment of Painful Neuropathy in Patients With Diabetes Mellitus: a Randomized Controlled Trial , 1999 .

[61]  W. Reid,et al.  Assessment of response to treatment in vulvar vestibulitis syndrome by means of the vulvar algesiometer. , 1999, American journal of obstetrics and gynecology.

[62]  J. Riley,et al.  A meta-analytic review of pain perception across the menstrual cycle , 1999, Pain.

[63]  R. Pagano.  Vulvar Vestibulitis Syndrome: An Often Unrecognized Cause of Dyspareunia , 1999, The Australian & New Zealand journal of obstetrics & gynaecology.

[64]  M. Rowbotham,et al.  Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. , 1998, JAMA.

[65]  J. Kocsis,et al.  A summary of mechanistic hypotheses of gabapentin pharmacology , 1998, Epilepsy Research.

[66]  H. Glazer,et al.  Establishing the diagnosis of vulvar vestibulitis. , 1997, The Journal of reproductive medicine.

[67]  D. Turk,et al.  A standardized manual tender point survey. I. Development and determination of a threshold point for the identification of positive tender points in fibromyalgia syndrome. , 1997, The Journal of rheumatology.

[68]  M. McKay,et al.  Dysesthetic ("essential") vulvodynia. Treatment with amitriptyline. , 1993, The Journal of reproductive medicine.

[69]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[70]  R H LaMotte,et al.  Pain, hyperalgesia and activity in nociceptive C units in humans after intradermal injection of capsaicin. , 1992, The Journal of physiology.

[71]  M. Goetsch.  Vulvar vestibulitis: prevalence and historic features in a general gynecologic practice population. , 1991, American journal of obstetrics and gynecology.

[72]  J. Ochoa,et al.  Heat and mechanical hyperalgesia induced by capsaicin. Cross modality threshold modulation in human C nociceptors. , 1989, Brain : a journal of neurology.

[73]  Robert H. LaMotte,et al.  Dose-dependent pain and mechanical hyperalgesia in humans after intradermal injection of capsaicin , 1989, Pain.

[74]  Huston Gj,et al.  The Hospital Anxiety and Depression Scale. , 1987, The Journal of rheumatology.

[75]  Friedrich Eg.  Vulvar vestibulitis syndrome. , 1987, The Journal of reproductive medicine.

[76]  Francis J. Keefe,et al.  The use of coping strategies in chronic low back pain patients: Relationship to patient characteristics and current adjustment , 1983, Pain.

[77]  H. Locke,et al.  SHORT MARITAL ADJUSTMENT AND PREDICTION TESTS: THEIR RELIABILITY AND VALIDITY , 1959 .

[78]  T. Gordi,et al.  Steady-state pharmacokinetics of gabapentin after administration of a novel gastroretentive extended-release formulation in postmenopausal women with vasomotor symptoms. , 2012, Clinical drug investigation.

[79]  A. Kesselheim,et al.  Meta-analyses involving cross-over trials: methodological issues. , 2011, International journal of epidemiology.

[80]  M. Wallace,et al.  Gabapentin Extended-Release Tablets for the Treatment of Patients with Postherpetic Neuralgia , 2010, Clinical drug investigation.

[81]  M. Chren,et al.  Effects of vulvodynia on quality of life. , 2009, Journal of the American Academy of Dermatology.

[82]  J. Stinson,et al.  Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society. , 2007, Pain research & management.

[83]  D. Gorenflo,et al.  Treatment of vulvodynia with tricyclic antidepressants: efficacy and associated factors. , 2006, Journal of lower genital tract disease.

[84]  D. Selvarajah,et al.  Morphine, gabapentin, or their combination for neuropathic pain. , 2005, The New England journal of medicine.

[85]  B. Harlow,et al.  A population-based assessment of chronic unexplained vulvar pain: have we underestimated the prevalence of vulvodynia? , 2003, Journal of the American Medical Women's Association.

[86]  Scott R. Bishop,et al.  The Pain Catastrophizing Scale: Development and validation. , 1995 .

[87]  D. Drossman,et al.  The reliability and validity of a sexual and physical abuse history questionnaire in female patients with gastrointestinal disorders. , 1995, Behavioral medicine.